http://www.sciencedaily.com/news/health_medicine/prostate_health/ Latest research news on prostate health. Find out about prostate cancer symptoms, enlarged prostate and other prostate problems. en-us Sat, 26 May 2012 14:05:01 EDT Sat, 26 May 2012 14:05:01 EDT 60 http://www.sciencedaily.com/images/logosmall.gif http://www.sciencedaily.com/news/health_medicine/prostate_health/ For more science articles, visit ScienceDaily. http://www.sciencedaily.com/releases/2012/05/120521213645.htm Following a period for public comment, the United States Preventive Services Task Force (USPSTF) released its final recommendation for prostate cancer screening. The Task Force now recommends against PSA-based screening for all men, regardless of age. Mon, 21 May 2012 21:36:36 EDT http://www.sciencedaily.com/releases/2012/05/120521213645.htm http://www.sciencedaily.com/releases/2012/05/120521115512.htm Statins drugs prescribed to treat high cholesterol may also work to slow prostate growth in men who have elevated PSA levels, according to a new analysis. Mon, 21 May 2012 11:55:55 EDT http://www.sciencedaily.com/releases/2012/05/120521115512.htm http://www.sciencedaily.com/releases/2012/05/120520133921.htm A collaborative expedition into the deep genetics of prostate cancer has uncovered a distinct subtype of the disease, one that appears to account for up to 15 percent of all cases, say researchers. Sun, 20 May 2012 13:39:39 EDT http://www.sciencedaily.com/releases/2012/05/120520133921.htm http://www.sciencedaily.com/releases/2012/05/120516195600.htm Researchers have demonstrated that a hormone-depleting drug approved for the treatment of metastatic prostate cancer can help eliminate or nearly eliminate tumors in many patients with aggressive cancers that have yet to spread beyond the prostate, according to a new clinical study. Wed, 16 May 2012 19:56:56 EDT http://www.sciencedaily.com/releases/2012/05/120516195600.htm http://www.sciencedaily.com/releases/2012/05/120504135929.htm Prostate cancer cells that defy treatment and display heightened tumor-generating capacity can be identified by levels of prostate specific antigen (PSA) expressed in the tumor cells, scientists have found. Fri, 04 May 2012 13:59:59 EDT http://www.sciencedaily.com/releases/2012/05/120504135929.htm http://www.sciencedaily.com/releases/2012/04/120424162224.htm Oregano, the common pizza and pasta seasoning herb, has long been known to possess a variety of beneficial health effects, but a new study indicates that an ingredient of this spice could potentially be used to treat prostate cancer, the second leading cause of cancer death in American men. Tue, 24 Apr 2012 16:22:22 EDT http://www.sciencedaily.com/releases/2012/04/120424162224.htm http://www.sciencedaily.com/releases/2012/04/120423132015.htm Scientists believe that two forms of vitamin E – gamma and delta-tocopherols – found in soybean, canola and corn oils as well as nuts do prevent colon, lung, breast and prostate cancers while the alpha tocopherols found in vitamin E supplements provide no such protection. Mon, 23 Apr 2012 13:20:20 EDT http://www.sciencedaily.com/releases/2012/04/120423132015.htm http://www.sciencedaily.com/releases/2012/04/120409164207.htm Investigators have discovered two inherited-genetic deletions in the human genome linked to development of aggressive prostate cancer. The findings indicate a man's risk of developing prostate cancer either triples or quadruples, depending on the genetic variant they inherit. Mon, 09 Apr 2012 16:42:42 EDT http://www.sciencedaily.com/releases/2012/04/120409164207.htm http://www.sciencedaily.com/releases/2012/04/120401105402.htm Low oxygen levels in tumors can be used to predict cancer recurrence in men with intermediate-risk prostate cancer even before they receive radiation therapy. Sun, 01 Apr 2012 10:54:54 EDT http://www.sciencedaily.com/releases/2012/04/120401105402.htm http://www.sciencedaily.com/releases/2012/03/120331151134.htm Higher oral doses of plain vitamin D raised levels of calcitriol in prostate tissue. Higher prostate levels of calcitriol, a hormone made from vitamin D, corresponded with lower levels of the proliferation marker Ki67 and increased levels of cancer growth-inhibitory microRNAs in prostate cancer cells, according to new data. Sat, 31 Mar 2012 15:11:11 EDT http://www.sciencedaily.com/releases/2012/03/120331151134.htm http://www.sciencedaily.com/releases/2012/03/120331151126.htm The use of metformin in men with prostate cancer before prostatectomy helped to reduce certain metabolic parameters and slow the growth rate of the cancer, according to new research. Sat, 31 Mar 2012 15:11:11 EDT http://www.sciencedaily.com/releases/2012/03/120331151126.htm http://www.sciencedaily.com/releases/2012/03/120312102148.htm A new analysis has found that circumcision before a male's first sexual intercourse may help protect against prostate cancer. The study suggests that circumcision can hinder infection and inflammation that may lead to this malignancy. Mon, 12 Mar 2012 10:21:21 EDT http://www.sciencedaily.com/releases/2012/03/120312102148.htm http://www.sciencedaily.com/releases/2012/02/120220161233.htm Genomic instability caused by an erosion of the protective caps on chromosomes, followed by activation of an enzyme that reinforces those caps, allows malignant cells to evade destruction and acquire more deadly characteristics, researchers report. Mon, 20 Feb 2012 16:12:12 EST http://www.sciencedaily.com/releases/2012/02/120220161233.htm http://www.sciencedaily.com/releases/2012/02/120210105859.htm Curcumin, an active component of the Indian curry spice turmeric, may help slow down tumor growth in castration-resistant prostate cancer patients on androgen deprivation therapy, a new study suggests. Fri, 10 Feb 2012 10:58:58 EST http://www.sciencedaily.com/releases/2012/02/120210105859.htm http://www.sciencedaily.com/releases/2012/02/120208132717.htm In a large analysis of men participating in a prostate drug trial, researchers found a significant correlation between coronary artery disease and prostate cancer, suggesting the two conditions may have shared causes. Wed, 08 Feb 2012 13:27:27 EST http://www.sciencedaily.com/releases/2012/02/120208132717.htm http://www.sciencedaily.com/releases/2012/02/120201093102.htm Involuntary childlessness owing to reduced fertility is a concern for many men. However, these men do have one advantage -- they run a significantly lower risk of suffering from prostate cancer. Wed, 01 Feb 2012 09:31:31 EST http://www.sciencedaily.com/releases/2012/02/120201093102.htm http://www.sciencedaily.com/releases/2012/01/120125162634.htm A population-based analysis looking at almost 13,000 cases revealed that men who received brachytherapy alone or in combination with external beam radiation therapy had significantly reduced mortality rates. Wed, 25 Jan 2012 16:26:26 EST http://www.sciencedaily.com/releases/2012/01/120125162634.htm http://www.sciencedaily.com/releases/2012/01/120111223742.htm After a 20-year quest to find a genetic driver for prostate cancer that strikes men at younger ages and runs in families, researchers have identified a rare, inherited mutation linked to a significantly higher risk of the disease. Wed, 11 Jan 2012 22:37:37 EST http://www.sciencedaily.com/releases/2012/01/120111223742.htm http://www.sciencedaily.com/releases/2012/01/120111223346.htm After a 20-year quest to find a genetic driver for prostate cancer that strikes men at younger ages and runs in families, researchers have identified a rare, inherited mutation linked to a significantly higher risk of the disease. Wed, 11 Jan 2012 22:33:33 EST http://www.sciencedaily.com/releases/2012/01/120111223346.htm http://www.sciencedaily.com/releases/2012/01/120109155946.htm Researchers created a drug delivery system that is able to effectively deliver a tremendous amount of chemotherapeutic drugs to prostate cancer cells. Mon, 09 Jan 2012 15:59:59 EST http://www.sciencedaily.com/releases/2012/01/120109155946.htm http://www.sciencedaily.com/releases/2012/01/120107151853.htm There's new evidence that annual prostate cancer screening does not reduce deaths from the disease, even among men in their 50s and 60s and those with underlying health conditions, according to new research. Sat, 07 Jan 2012 15:18:18 EST http://www.sciencedaily.com/releases/2012/01/120107151853.htm http://www.sciencedaily.com/releases/2012/01/120105174228.htm Proton therapy, a type of external beam radiation therapy, is a safe and effective treatment for prostate cancer, according to two new studies. Thu, 05 Jan 2012 17:42:42 EST http://www.sciencedaily.com/releases/2012/01/120105174228.htm http://www.sciencedaily.com/releases/2011/11/111121194037.htm Scientists have designed a first draft of a mathematical model that someday could guide treatment decisions for advanced prostate cancer, in part by helping doctors predict how individual patients will respond to therapy based on the biology of their tumors. These decisions would apply to treatment of cancer that has already spread beyond the prostate gland or that has recurred after initial treatments, such as surgery or radiation. Mon, 21 Nov 2011 19:40:40 EST http://www.sciencedaily.com/releases/2011/11/111121194037.htm http://www.sciencedaily.com/releases/2011/11/111117083230.htm A recent report suggests that a new treatment may be on the horizon for neuroendocrine prostate cancers, the most lethal subtype of this disease. Thu, 17 Nov 2011 08:32:32 EST http://www.sciencedaily.com/releases/2011/11/111117083230.htm http://www.sciencedaily.com/releases/2011/11/111114221021.htm Use of the contraceptive pill is associated with an increased risk of prostate cancer around the globe, new research finds. Mon, 14 Nov 2011 22:10:10 EST http://www.sciencedaily.com/releases/2011/11/111114221021.htm http://www.sciencedaily.com/releases/2011/11/111102093049.htm Researchers in Australia have discovered a potential future treatment for prostate cancer -- through starving the tumor cells of an essential nutrient they need to grow rapidly. Their work, with human cells grown in the lab, reveals targets for drugs that could slow the progress of early and late stage prostate cancer. Wed, 02 Nov 2011 09:30:30 EDT http://www.sciencedaily.com/releases/2011/11/111102093049.htm http://www.sciencedaily.com/releases/2011/11/111101125824.htm For prostate cancer patients with bone metastases, repeated administrations of radionuclide therapy with 188Re-HEDP are shown to improve overall survival rates and reduce pain, according to new research. Tue, 01 Nov 2011 12:58:58 EDT http://www.sciencedaily.com/releases/2011/11/111101125824.htm http://www.sciencedaily.com/releases/2011/10/111031154129.htm Men with prostate cancer are twice as likely to commit suicide, but a method where they put intrusive thoughts into words may reduce this risk, reveals research from Sweden. Mon, 31 Oct 2011 15:41:41 EDT http://www.sciencedaily.com/releases/2011/10/111031154129.htm http://www.sciencedaily.com/releases/2011/10/111025135931.htm A low-fat diet with fish oil supplements eaten for four to six weeks prior to prostate removal slowed down the growth of prostate cancer cells -- the number of rapidly dividing cells -- in human prostate cancer tissue compared to a traditional, high-fat Western diet, according to a new study. Tue, 25 Oct 2011 13:59:59 EDT http://www.sciencedaily.com/releases/2011/10/111025135931.htm http://www.sciencedaily.com/releases/2011/10/111021195456.htm The prostate-specific antigen test, commonly known as the PSA test, is valuable in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer, a new study has found. Fri, 21 Oct 2011 19:54:54 EDT http://www.sciencedaily.com/releases/2011/10/111021195456.htm http://www.sciencedaily.com/releases/2011/10/111021162253.htm Recent studies have suggested that C-11 choline positron emission tomography/computerized tomography scans can be utilized as a staging and potentially therapeutic tool in prostate cancer. Fri, 21 Oct 2011 16:22:22 EDT http://www.sciencedaily.com/releases/2011/10/111021162253.htm http://www.sciencedaily.com/releases/2011/10/111019195407.htm Contrary to common belief, men age 75 and older are diagnosed with late-stage and more aggressive prostate cancer and thus die from the disease more often than younger men, according to a new analysis. Wed, 19 Oct 2011 19:54:54 EDT http://www.sciencedaily.com/releases/2011/10/111019195407.htm http://www.sciencedaily.com/releases/2011/10/111017092237.htm Researchers have discovered that a gene -- known as an androgen receptor (AR) -- is found in both prostate and breast cancers yet has opposite effects on these diseases. In prostate cancer, the AR gene promotes cancer growth when the gene is "turned on." In breast cancer, the AR gene promotes cancer growth when the gene is "turned off," as is often the case after menopause, when AR production ceases in women. Mon, 17 Oct 2011 09:22:22 EDT http://www.sciencedaily.com/releases/2011/10/111017092237.htm http://www.sciencedaily.com/releases/2011/10/111011163055.htm Men who take a daily vitamin E supplement -- a regimen once thought to reduce cancer risk -- face an increased risk of prostate cancer, according to results of a large national study. The finding comes from a report summarizing the latest results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Tue, 11 Oct 2011 16:30:30 EDT http://www.sciencedaily.com/releases/2011/10/111011163055.htm http://www.sciencedaily.com/releases/2011/10/111011163049.htm Men who took 400 international units of vitamin E daily had more prostate cancers compared to men who took a placebo. The findings showed that, per 1,000 men, there were 76 prostate cancers in men who took only vitamin E supplements, vs. 65 in men on placebo over a seven-year period, or 11 more cases per 1,000 men. This represents a 17 percent increase in prostate cancers relative to those who took a placebo. Tue, 11 Oct 2011 16:30:30 EDT http://www.sciencedaily.com/releases/2011/10/111011163049.htm http://www.sciencedaily.com/releases/2011/10/111011163043.htm In a trial that included about 35,000 men, those who were randomized to receive daily supplementation with vitamin E had a significantly increased risk of prostate cancer, according to a new study. Tue, 11 Oct 2011 16:30:30 EDT http://www.sciencedaily.com/releases/2011/10/111011163043.htm http://www.sciencedaily.com/releases/2011/10/111005142458.htm There are three major factors that are used to evaluate the extent and aggressiveness of prostate cancer, help make treatment decisions, and estimate prognosis: the prostate specific antigen level, Gleason score from the biopsy, and the digital rectal exam findings. However, men with a family history of prostate cancer have often been feared to have a more aggressive form of the disease not otherwise represented by these three factors and therefore are sometimes urged to undergo more aggressive treatment. Now, a radiation oncologist reports that men with a family history of prostate cancer should expect equally good outcomes following radiotherapy for prostate cancer as patients without a family history. Wed, 05 Oct 2011 14:24:24 EDT http://www.sciencedaily.com/releases/2011/10/111005142458.htm http://www.sciencedaily.com/releases/2011/10/111005122230.htm Prostate cancer is the most common cancer in men in the United States, as well as the second leading cause of cancer-related deaths in this population. Many of these patients undergo surgical removal of their prostate, followed by radiation therapy applied to their prostate bed -- the space where the prostate was once situated. Wed, 05 Oct 2011 12:22:22 EDT http://www.sciencedaily.com/releases/2011/10/111005122230.htm http://www.sciencedaily.com/releases/2011/10/111005111404.htm After a prostate cancer patient receives radiation treatment, his doctor carefully monitors the amount of prostate-specific antigen, or PSA, in his blood. An increase in PSA, called biochemical failure, is the first detectable sign of the cancer's return to the prostate. A researcher have found that the time between the last radiation treatment and biochemical failure can accurately predict a patient's risk of death of prostate cancer. Wed, 05 Oct 2011 11:14:14 EDT http://www.sciencedaily.com/releases/2011/10/111005111404.htm http://www.sciencedaily.com/releases/2011/10/111005111402.htm In a new study, researchers have found that Gleason scores determined by pathologists at Fox Chase Cancer Center more accurately predict the risk of recurrence than Gleason scores from referring institutions. Wed, 05 Oct 2011 11:14:14 EDT http://www.sciencedaily.com/releases/2011/10/111005111402.htm http://www.sciencedaily.com/releases/2011/10/111003080521.htm The invasion of a new species into an established ecosystem can be directly compared to the steps involved in cancer metastasis. New research uses the Tilman model of competition between invasive species to study the metastasis of prostate cells into bone. Mon, 03 Oct 2011 08:05:05 EDT http://www.sciencedaily.com/releases/2011/10/111003080521.htm http://www.sciencedaily.com/releases/2011/09/110928125410.htm Scientists believe they have found an effective target for killing late-stage, metastatic prostate cancer cells. They are focusing on the function of a gene called Polo-like kinase (Plk1), a critical regulator of the cell cycle. Plk1 is also an oncogene, which tends to mutate and can cause cancer. Wed, 28 Sep 2011 12:54:54 EDT http://www.sciencedaily.com/releases/2011/09/110928125410.htm http://www.sciencedaily.com/releases/2011/09/110927161658.htm The most widely used over-the-counter supplement for prostate health is no more effective than a placebo in treating men's lower urinary tract symptoms, according to new findings. Tue, 27 Sep 2011 16:16:16 EDT http://www.sciencedaily.com/releases/2011/09/110927161658.htm http://www.sciencedaily.com/releases/2011/09/110927161656.htm The fruit of the saw palmetto tree does not relieve symptoms of an enlarged prostate, even when men take the herbal supplement in very high doses, a new study shows. Tue, 27 Sep 2011 16:16:16 EDT http://www.sciencedaily.com/releases/2011/09/110927161656.htm http://www.sciencedaily.com/releases/2011/09/110926173131.htm It's an ongoing debate: should men over a certain age be treated for prostate cancer? Should these patients be submitted to treatments that may result in significant side effects if they may not live very much longer? Now, a study has shown that men over 75 with prostate cancer are being undertreated, while patients with a single comorbid condition such as peripheral vascular disease or those in wheelchairs are being over-treated and doing much more poorly than expected. Mon, 26 Sep 2011 17:31:31 EDT http://www.sciencedaily.com/releases/2011/09/110926173131.htm http://www.sciencedaily.com/releases/2011/09/110926151731.htm Researchers have conducted the first comprehensive assessment of every gene in the genome of advanced, lethal prostate cancer. Until now, the genetic composition of such tumors had been poorly defined. Mon, 26 Sep 2011 15:17:17 EDT http://www.sciencedaily.com/releases/2011/09/110926151731.htm http://www.sciencedaily.com/releases/2011/09/110926144559.htm A shorter course of radiation treatment that delivers higher doses of radiation per day in fewer days (hypofractionation) is as effective in decreasing intermediate to high-risk prostate cancer from returning as conventional radiation therapy at five years after treatment, according to a new randomized trial. Mon, 26 Sep 2011 14:45:45 EDT http://www.sciencedaily.com/releases/2011/09/110926144559.htm http://www.sciencedaily.com/releases/2011/09/110925125159.htm Men with prostate cancer that has spread to other parts of the body and that is resistant to hormone therapy suffer less from fatigue if they are treated with a combination of abiraterone acetate and prednisone, according to a new study. Significant improvements in fatigue are important for this group of difficult-to-treat patients who had few available therapeutic options, and for whom fatigue is one of the most distressing issues they face. Sun, 25 Sep 2011 12:51:51 EDT http://www.sciencedaily.com/releases/2011/09/110925125159.htm http://www.sciencedaily.com/releases/2011/09/110924184752.htm Inhibiting a protein involved in bone metabolism can delay the onset of bone metastases common in men with prostate cancer resistant to hormone treatment. The research on the effects of the monoclonal antibody denosumab is the first large-scale clinical trial to show such an effect. The use of denosumab in this group of patients can impede the onset of bone metastases by just over four months. Sat, 24 Sep 2011 18:47:47 EDT http://www.sciencedaily.com/releases/2011/09/110924184752.htm http://www.sciencedaily.com/releases/2011/09/110923194732.htm The first Phase III study of an alpha-pharmaceutical (Radium-223 Chloride -- Alpharadin) in patients with bone metastases from advanced prostate cancer has shown that it can prolong survival significantly. Until now, options for these patients have been very limited. The ALSYMPCA trial had to be stopped early after interim analysis revealed that patients receiving the best standard treatment plus radium-223 were living longer than those who were receiving the same standard treatment plus placebo. Fri, 23 Sep 2011 19:47:47 EDT http://www.sciencedaily.com/releases/2011/09/110923194732.htm http://www.sciencedaily.com/releases/2011/09/110923194727.htm Two related studies reveal new risk indicators for prostate cancer. The first study shows that men diagnosed with benign prostate enlargement have an increased risk of developing and dying from prostate cancer. The second study shows that monitoring prostate-specific antigen levels can be used to predict the long-term risk of healthy men developing and dying from prostate cancer. Both could lead to more efficient and cost-effective screening for prostate cancer, with reductions in over-diagnosis and unnecessary treatment. Fri, 23 Sep 2011 19:47:47 EDT http://www.sciencedaily.com/releases/2011/09/110923194727.htm http://www.sciencedaily.com/releases/2011/09/110922093326.htm Researchers have developed a way to image the spread of a particularly dangerous form of prostate cancer earlier than conventional imaging in use today, which may allow oncologists to find and treat these metastases more quickly and give patients a better chance at survival. Thu, 22 Sep 2011 09:33:33 EDT http://www.sciencedaily.com/releases/2011/09/110922093326.htm http://www.sciencedaily.com/releases/2011/09/110922093319.htm In a study of complication rates following prostate biopsy among Medicare beneficiaries, researchers have found a significant rise in serious complications requiring hospitalization. The researchers found that this common outpatient procedure, used to diagnose prostate cancer, was associated with a 6.9 percent rate of hospitalization within 30 days of biopsy compared to a 2.9 percent hospitalization rate among a control group of men who did not have a prostate biopsy. Thu, 22 Sep 2011 09:33:33 EDT http://www.sciencedaily.com/releases/2011/09/110922093319.htm http://www.sciencedaily.com/releases/2011/09/110920100051.htm Genetic differences in prostate cells seem to be a root cause of the prostate cancer disparities between African-American men and white men, according to new findings. Tue, 20 Sep 2011 10:00:00 EDT http://www.sciencedaily.com/releases/2011/09/110920100051.htm http://www.sciencedaily.com/releases/2011/09/110919073851.htm Scientists have pioneered a new combination treatment for prostate cancer. The treatment, which has been successful in phase one of trials, will now be tested for efficacy in a second phase. Mon, 19 Sep 2011 07:38:38 EDT http://www.sciencedaily.com/releases/2011/09/110919073851.htm http://www.sciencedaily.com/releases/2011/09/110916131259.htm A new study suggests that a high intake of calcium can cause prostate cancer among African-American men who are genetically good absorbers of the mineral. Fri, 16 Sep 2011 13:12:12 EDT http://www.sciencedaily.com/releases/2011/09/110916131259.htm http://www.sciencedaily.com/releases/2011/08/110816133056.htm Researchers have identified five inherited genetic variants that are strongly associated with aggressive, lethal prostate cancer. The discovery ultimately could lead to the development of a simple blood test that could be given upon diagnosis to determine which men should receive aggressive treatment versus a more conservative "watchful waiting" approach. Tue, 16 Aug 2011 13:30:30 EDT http://www.sciencedaily.com/releases/2011/08/110816133056.htm http://www.sciencedaily.com/releases/2011/08/110815111215.htm A new prostate screening test may prove to be a promising new tool in the diagnosis of prostate cancer. The study found that this new screening test, the PSA/SIA assay, may be more sensitive in detecting prostate cancer than traditional screening methods. Mon, 15 Aug 2011 11:12:12 EDT http://www.sciencedaily.com/releases/2011/08/110815111215.htm http://www.sciencedaily.com/releases/2011/08/110812091811.htm Prostate cancer that has become resistant to hormone treatment and that does not respond to radiation or chemotherapy requires new methods of treatment. By attacking stem cell-like cells in prostate cancer, researchers are working on a project to develop a new treatment option. Fri, 12 Aug 2011 09:18:18 EDT http://www.sciencedaily.com/releases/2011/08/110812091811.htm http://www.sciencedaily.com/releases/2011/08/110808115405.htm Nearly half of men undergoing surgery for prostate cancer expect better recovery from the side effects of the surgery than they actually attain one year after the operation, a new study finds. Mon, 08 Aug 2011 11:54:54 EDT http://www.sciencedaily.com/releases/2011/08/110808115405.htm